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Twitter 
Low lung function associates with menopause, especially if it occurs early in life.  
1 
 
ABSTRACT 
Little is known about the effect of cessation of menstruation on lung function. The aims of 
the study were to examine the association of lung function with natural and surgical cessation 
of menstruation, and assess whether lower lung function is associated with earlier age at 
cessation of menstruation. 
 
The study was performed in 141,076 women from the UK Biobank, who had provided 
acceptable and reproducible spirometry measurements and information on menstrual status. 
The associations of lung function [FVC, FEV1, spirometric restriction (FVC<LLN), airflow 
obstruction (FEV1/FVC<LLN)] with cessation of menstruation and age at cessation of 
menstruation were assessed using regression analysis. 
 
Women who had natural cessation of menstruation showed a lower FVC (-42mL; 95%CI -53, 
-30) and FEV1 (-34mL/s; 95%CI -43, -24) and higher risk of spirometric restriction 
(adjOR=1.27; 95%CI 1.18-1.37) than women still menstruating. These associations were 
stronger in women who had had a hysterectomy and/or oophorectomy. The earlier the natural 
cessation of menstruation, the lower the lung function. There was no clear association of lung 
function with age at hysterectomy and/or oophorectomy. Airflow obstruction was not 
associated with cessation of menstruation. 
 
Lower lung function associates with cessation of menstruation, especially if it occurs early in 
life. 
 
Abstract word count: 197 Key words: lung function; menopause; hysterectomy; 
restriction; epidemiology    
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INTRODUCTION 
In adult men and women, low lung function is a major predictor of mortality, even in non-
smokers and in those without symptoms of lung disease (1, 2). Although many authors have 
linked this to forced expiratory volume in 1 second (FEV1) and airflow obstruction, more 
recent work has shown that the strong association is between mortality and forced vital 
capacity (FVC), rather than airflow obstruction (1, 3). Multiple risk factors for low lung 
function have been put forward, including early life exposures, lifestyle factors (mainly 
smoking), environmental and occupational exposures, and the presence of asthma at any 
point during lifetime (4). These may operate by causing poor lung development in utero or 
during childhood, leading to failure to achieve maximal lung function early in life, or through 
more rapid decline in lung function with age during adulthood. 
Differences in lung development and lung function between males and females are present 
throughout the life course and have been attributed to sex-specific responses to environmental 
or lifestyle insults and to effect of sex hormones (5, 6). Menopause, the cessation of 
menstruation, usually in response to a natural age-related decline in sex hormones commonly 
occurs between 45 and 55 years of age, although there is considerable variation (7, 8). 
Cessation of menstruation is sometimes precipitated by surgical interventions such as 
oophorectomy and hysterectomy. In young women, these interventions may prompt the 
prescription of hormone replacement therapy (HRT). 
The cessation of menstruation has been examined in relation to several chronic diseases and 
health parameters, but little is known about its effect on lung function. Epidemiologic 
evidence on the association of menopause with lung function is limited, conflicting, 
inconclusive, and based largely on underpowered cross-sectional studies. In two studies with 
a combined total of less than 3300 women, the European Community Respiratory Health 
Survey II and the Mater University of Queensland Study of Pregnancy, menopause was 
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associated with both lower FEV1 and FVC (9, 10). In a smaller study, the Isparta Menopause 
and Health Study, menopause was associated with lower FEV1 and FVC, but this was 
explained by age, and it was not associated with airflow obstruction (11). In contrast, another 
cross-sectional study of just over 3700 women from the Health Survey for England, natural 
and surgical cessation of menstruation were associated with less airflow obstruction and 
natural menopause was associated with higher FEV1, although only in women aged 55 to 64 
(12). 
Most women undergo natural menopause, i.e. natural cessation of menstruation, around the 
age of 50 years (8), which means that with increasing life expectancy they will spend a large 
part of their lives in a postmenopausal state. Thus, it is important to expand our 
understanding of the impact that menopause and other types of cessation of menstruation 
have on the lung. 
The aims of this study were to: 1) examine the association of lung function with natural and 
surgical cessation of menstruation in the population-based sample of the UK Biobank; and 2) 
assess whether lower lung function is associated with earlier age at natural menopause. 
 
METHODS 
Study participants 
UK Biobank is a very large multi-centre population-based study, established to allow the 
identification and improved understanding of the genetic and non-genetic determinants of 
disease in middle-aged and elder adults (13). The 273,467 women who took part in the UK 
Biobank were assessed, between 2006 and 2010, in 22 centres across England, Wales, and 
Scotland located in areas with sufficient population aged 40 to 69 living within 10 miles (16.1 
km) of the testing centre. During assessment, participants completed a touchscreen 
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questionnaire to provide information on their lifestyle, medical and family history, and 
underwent physical measurements, including spirometry. 
The UK National Research Ethics Service Committee North West – Haydock approved the 
study, and electronic written consent from each participant was obtained. 
 
Lung function outcomes 
Lung function was assessed, in each centre, by nurses or healthcare technicians trained in 
spirometry following a standard protocol and using a Vitalograph Pneumotrac 6800 
spirometer (Vitalograph Ltd., Buckingham, UK). Participants did not perform spirometry if 
they answered ‘yes’ or were unsure of the following: chest infection in the last month (i.e., 
influenza, bronchitis, severe cold, pneumonia); history of detached retina; heart attack or 
surgery to eyes, chest or abdomen in last three months; history of collapsed lung; pregnancy 
(first or third trimester); and currently on medication for tuberculosis. The aim was to record 
two acceptable blows from a maximum of three attempts. The spirometer software compared 
the acceptability of the first two blows and, if acceptable (defined as a ≤ 5% difference in 
FVC and FEV1), indicated to the fieldworkers that the third blow was not required. Post-
bronchodilator measurements were not performed. Analyses in this report were conducted 
using data from women who had provided at least two spirograms complying with the 
following criteria: 1) without cough; 2) back-extrapolated volume <5% FVC (or <150mL if 
greater); 3) flow <25mL in final 1s of forced expiratory time (FET); 4) both FEV1 and FVC 
reproducible; and 5) FET ≥6s on best curve (highest FEV1+FVC) (figure 1). 
Outcome measures were: i) FVC; ii) FEV1; iii) spirometric restriction, defined as 
FVC<lower limit of normal (LLN) for age and height, based on reference equations for 
Caucasians from the third US National Health and Nutrition Examination Survey (NHANES) 
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(14); and iv) airflow obstruction, defined as FEV1/FVC<LLN, based on the same reference 
population. 
Menstrual status 
Menstrual status was considered in six groups (regular menstruation; irregular menstruation; 
natural menopause; hysterectomy only; oophorectomy only; oophorectomy + hysterectomy) 
and their definition was based on a series of questions. Women who replied ‘no’ to the 
question “have you had your menopause (periods stopped)?” were also asked “how many 
days is your usual menstrual cycle?” If they provided a number to this question, they were 
classified as having ‘regular menstruation’ (median menstrual cycle length was 28 days, IQR 
25-28). If they chose the option ‘irregular cycle’ they were classified as having ‘irregular 
menstruation’. 
Women were considered to have had ‘natural menopause’ if they replied ‘yes’ to the question 
on menopause and ‘no’ to both “have you had both ovaries removed?” (oophorectomy) and 
“have you had a hysterectomy (womb removed)?” (hysterectomy). Those whose ovaries 
and/or uterus were removed after their natural cessation of menstruation were classified has 
having had ‘natural menopause’. Women were classified into three other groups depending 
on the type of surgical cessation of menstruation: ‘hysterectomy only’; ‘oophorectomy only’; 
and ‘oophorectomy+hysterectomy’. Women unsure whether they had menopause were 
excluded from the analysis.  
 
Statistical analysis 
Following exclusions of women who had used an inhaler in the last hour prior to spirometry, 
women unsure whether they had menopause, those who were pregnant or reported a history 
of gynaecological cancer, and those who had reported an age at menopause less than 35 or 
greater than 65, the final sample for analysis comprised of 141,076 women. 
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The association of menstrual status with FVC and FEV1 was examined using linear 
regression. For the association with FVC<LLN and FEV1/FVC<LLN, logistic regression was 
used instead. Three models adjusting for potential confounders were used: Model 1, adjusted 
for recruitment centre, age (restricted cubic splines with five knots), ethnicity (White, non-
White), standing height (continuous), and Townsend deprivation index (continuous); Model 
2, further adjusted for reproductive characteristics [age at menarche (continuous), oral 
contraceptive ever use (yes, no), hormone replacement therapy (HRT) use (never, ex-user, 
current user), and number of live births (0, 1, 2, 3, 4, 5+)]; and Model 3, further adjusted for 
lifestyle-related characteristics [smoking status (lifetime non-smoker, ex-smoker, current 
smoker), pack-years (continuous), and body mass index (BMI; <18.5 kg/m2, 18.5-24.99 
kg/m2, 25.00-29.99 kg/m2, >29.99 kg/m2)]. In a sensitivity analysis, the associations of lung 
function with menstrual status were re-examined excluding women: 1) of non-White 
ethnicity; 2) with self-reported doctor-diagnosed asthma and/or chronic obstructive 
pulmonary disease (COPD); 3) who ever used HRT; 4) who ever smoked; and 5) those with 
an extreme BMI (<18.5 kg/m2 or >29.99 kg/m2). 
The association of lung function with natural menopause was further assessed by age group 
(age quintiles among women who had ceased menstruating) and according to age at 
menopause [<45 years (10%), 45-47 years (15%), 48-53 years (50%), 54-55 years (15%), 
56+ years (10%)], with natural menopause between the age of 48 and 53 as reference. In 
order to examine whether surgical cessation of menstruation is worse than natural cessation, 
similar analyses were carried out for hysterectomy only and oophorectomy+hysterectomy 
among women who have never taken HRT. These analyses were not carried out for women 
who had had an oophorectomy only due to the small size of this group (n=214). 
Results were considered statistically significant when P was less than 0.05. Statistical 
analysis was performed using Stata v.14 (StataCorp LP, College Station, TX). 
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RESULTS 
Characteristics of the 141,076 women included in this study are shown in table 1. As 
compared to women with regular or irregular menstruation, women who had stopped 
menstruating were older, more likely to be ex-smokers, and less likely to have ever used a 
contraceptive pill. More than two thirds of the women who had had surgical cessation of 
menstruation were ex- or current users of HRT. Ever users of HRT were more likely to be 
ever smokers and heavier than those who have never taken HRT (supplementary table 1). 
The prevalence of spirometric restriction was higher in women who had stopped 
menstruating, while the prevalence of airflow obstruction was slightly higher in women still 
menstruating. Both FEV1 and FVC were lower in women who had stopped menstruating. 
Just over half of the women who had natural menopause reported their last menstruation to 
have occurred at an age between 48 and 53 years. Most women who had undergone surgical 
cessation of menstruation, had their surgical intervention before they were 48 years of age 
(supplementary figure 1). 
Women excluded from the analyses due to low quality of spirometric data were similar to 
those included (supplementary table 2). 
 
Association of lung function with natural cessation of menstruation 
After full adjustment (model 3), women with irregular menstruation and natural menopause 
showed lower FVC [irregular menstruation: -17 mL (95%CI -31, -3); natural menopause: -42 
mL (95%CI -53, -30)], lower FEV1 [irregular menstruation: -12 mL/s (95%CI -24, 0); natural 
menopause: -34 mL/s (95%CI -43, -24)] and higher risk of spirometric restriction [irregular 
menstruation: odds ratio (OR)=1.16 (95%CI 1.05-1.28); natural menopause (OR=1.27 
(95%CI 1.18-1.37)] than those still menstruating. There was no association of airflow 
obstruction with irregular menstruation or natural menopause (table 2). 
8 
 
Sensitivity analyses restricted to 33,406 white women, who have never smoked, have a BMI 
of 18.5-29.99 kg/m2, do not have doctor-diagnosed asthma or COPD, and have never used 
HRT did not materially alter the results reported above (table 2; supplementary table 4). 
 
Association of lung function with surgical cessation of menstruation 
Women who had undergone hysterectomy, oophorectomy or both had lower FVC 
[hysterectomy only: -51 mL (95%CI -64, -37); oophorectomy only: -90 mL (95%CI -159, -
20); oophorectomy+hysterectomy: -54 mL (95%CI -69, -39)], lower FEV1 [hysterectomy 
only: -32 mL/s (95%CI -43, -20); oophorectomy only: -46 mL/s (95%CI -105, 12); 
oophorectomy+hysterectomy: -33 mL/s (95%CI -46, -21)] and higher risk of spirometric 
restriction [hysterectomy only: OR=1.31 (95%CI 1.20-1.43), oophorectomy only: OR=1.69 
(95%CI 1.14-2.50); oophorectomy+hysterectomy: OR=1.36 (95%CI 1.24-1.50)] than women 
who were menstruating regularly. These associations were present even after sensitivity 
analyses. Although there was some evidence that women who had hysterectomy with or 
without oophorectomy showed a lower risk of airflow obstruction, this observation was not 
seen after sensitivity analyses (table 2; supplementary table 4). 
 
Effect of age at natural menopause and surgical cessation of menstruation on lung 
function 
Among postmenopausal women, the earlier the natural menopause, the lower the FVC (and 
FEV1) and higher the risk of spirometric restriction (figures 2 and 3; supplementary tables 5-
7). There was no clear association of airflow obstruction with age at natural menopause 
(figure 4; supplementary table 8) nor of lung function with age at surgical cessation of 
menstruation, i.e. hysterectomy only or oophorectomy+hysterectomy (supplementary tables 
9-10). 
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DISCUSSION 
In this population-based study of adult women, lower FVC and an increased risk of 
spirometric restriction were associated with natural and surgical cessation of menstruation, as 
compared with regular menstruation. The associations with natural menopause were stronger 
among women who ceased menstruating at an earlier age. These findings were unlikely to be 
confounded by smoking as they were observed in women who were lifetime non-smokers. 
 
The strengths of our study are: 1) a very large sample size, which allows for more precise 
effect estimates; 2) the use of a standardised questionnaire for collection of data and protocol 
for spirometry across sites; 3) the use of spirometric measurements with the best quality only; 
and 4) the adjustment of models for a large set of confounders, including reproductive and 
lifestyle-related characteristics. 
 
Our study also has limitations. As with all cross-sectional studies, we are unable to draw firm 
conclusions in terms of temporality. However, we think it is unlikely that low lung function 
leads to menopause. We are aware that women who smoke tend to have earlier menopause 
(15), and also low lung function, but as the study is of considerable size, we were able to 
restrict analyses to a large group of women who have never smoked and see that our findings 
were unaltered. Both lung function later in life and age at menopause have been associated 
with socioeconomic status in childhood (16, 17), but we do not have this information. We 
have adjusted for the Townsend deprivation index of place of residence at the time of 
assessment. Some women were unsure whether they were menopausal or not, and they were 
excluded from all analyses. It is difficult to predict how the inclusion of these women would 
affect our results, but since they were likely perimenopausal (median age: 51; IQR 48-53) 
and their median FVC (3.31 L) and FEV1 (2.57 L/s) were between those of women with 
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irregular menstruation (FVC: 3.45 L; FEV1: 2.70 L/s) and women who had undergone 
natural menopause (FVC: 3.02; FEV1: 2.30 L/s) it is unlikely that our findings would be 
different. Those who were included might have responded incorrectly regarding their 
menstrual status, but this is likely a non-differential misclassification error leading to 
underestimation of true effects rather than biased estimates. It is possible that women with 
worse lung function, and early menopause, have died younger, meaning that the associations 
between menopause and lung function in the older groups may be diluted even further. 
Endometriosis, an indication for oophorectomy without hysterectomy in young women, has 
been associated with asthma, but this condition was rare (<2.5%) in women who had both 
ovaries removed. At the assessment centres, spirometry testing did not follow the ATS/ERS 
recommendation of performing at least three manoeuvres to measure FVC and FEV1, but we 
have used only spirometric data that fulfilled all other between- and within-manoeuvre 
criteria (18). Because we used pre-bronchodilator instead of post-bronchodilator spirometry, 
we were unable to distinguish COPD from asthma based on lung function. However, the 
association of airflow obstruction with cessation of menstruation was null. Some could argue 
that our results may be dependent on the reference equations we used (NHANES), but we 
obtained very similar results using the Global Lungs Initiative equations (19) (data not 
shown).  
 
To date, this is by far the largest population-based study to assess the association between 
lung function and menstrual status. The inverse association of FVC and FEV1 with natural 
menopause is consistent with two previous reports. Real et al. studied 1274 women from 
Europe and the USA and reported much lower FVC and FEV1 in women who had stopped 
menstruating for at least six months, as compared to women with regular menstruation (9). In 
an Australian study with 2020 women, Hayatbakhsh et al. reported a lower FVC and FEV1 in 
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postmenopausal women as opposed to premenopausal women (10). These studies reported 
much larger differences in FVC (Real et al.: -115 mL; Hayatbakhsh et al.: -60 mL) and FEV1 
(Real et al.: -120 mL/s; Hayatbakhsh et al.: -80 mL/s), but their studies were smaller and their 
analyses were adjusted for considerably less confounders. In contrast, Songur et al. studied 
1070 Turkish women and reported no difference in FVC or FEV1 between pre- and 
postmenopausal women (11). Like Real et al. (9), they also showed no association of 
menopause with airflow obstruction. In an English study with 3724 women, Jarvis and 
Leynaert reported less airflow obstruction in women who had either natural or surgical 
cessation of menstruation, as compared to menstruating women, but they only observed this 
amongst those aged 55 to 64 years (12). We observed less airflow obstruction in women who 
have undergone surgical cessation of menstruation, but this may have been due to use of HRT 
since exclusion of women who had used this therapy made the association disappear. This 
finding is supported by at least a population-based observational study and two trials showing 
better lung function (FVC and FEV1) in postmenopausal women taking HRT (20-22). None 
of these studies assessed the association of cessation of menstruation with spirometric 
restriction. Previous studies have also not examined the effect of different ages at natural 
menopause, or surgical cessation of menstruation, on lung function. 
 
The biological mechanisms underlying the association of a lower lung function with cessation 
of menstruation are not fully understood, but may be related to changes in the levels of 
circulating sex hormones and increased insulin resistance (23). It has been speculated that 
with cessation of menstruation the female body may reduce its capacity to detoxify, 
potentiating the bioaccumulation of chemicals, such as those found in cigarette smoke (24), 
to levels that could have adverse effects on the lungs. Accelerated bone mass loss (25) and 
weakened ligaments, which commonly follow the cessation of menstruation, could eventually 
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lead to compression and/or fracture of the vertebrae (26) and/or slippage of the ribs, 
constricting the lungs and reducing their volume, hence increasing the risk of restrictive lung 
condition. Medical interventions to treat osteoporotic vertebral compression fractures have 
been shown to lead to an increase in the FVC (27, 28). Another explanation for worse lung 
function in women who had an early cessation of menstruation may reside on ‘biological 
aging’. Some studies have shown lower FVC and FEV1 in those with shorter leukocyte 
telomeres (a marker of faster biological aging) (29, 30), which in turn have been suggested to 
be a marker of early menopause (31). 
 
In summary, lower lung function, particularly lower FVC, associates with cessation of 
menstruation. Although more research on this topic is needed and longitudinal studies would 
be welcome, our findings, together with evidence that low lung function and an early age at 
menopause have both been associated with increased mortality (3, 32), should alert clinicians 
to the risk of poor lung function in postmenopausal women, especially in those who have an 
early cessation of menstruation. 
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Table 1. Characteristics of women in UK Biobank included in this study. 
 
Regular 
menstruation 
Irregular 
menstruation 
Natural 
menopause 
Surgical interventions before menopause 
Total population 
 Hysterectomy only 
Oophorectomy 
only 
Oophorectomy + 
hysterectomy 
N 29,249 6,058 83,023 12,551 214 9,981 141,076 
Age (years), median (IQR) 45 (43-49) 48 (45-51) 60 (56-64) 61 (55-64) 57 (51-63) 61 (55-64) 58 (50-63) 
Age at menarche (years), median (IQR)‡ 13 (12-14) 13 (12-14) 13 (12-14) 13 (12-14) 13 (12-14) 13 (12-14) 13 (12-14) 
Age at cessation of menstruation (years), 
median (IQR)* 
- - 51 (48-53) 41 (38-45) 44 (37-50) 46 (41-50) - 
Ethnicity (%)        
     White 92.4 95.3 96.3 96.0 92.1 95.6 95.8 
     Non-White 7.6 4.7 3.7 4.0 7.9 4.4 4.2 
Standing height (cm), median (IQR)** 164 (160-168) 164 (160-168) 162 (158-166) 162 (158-166) 161 (158-166) 162 (157-166) 162 (158-167) 
BMI (kg/m2), median (IQR)*** 25.3 (22.8-28.8) 25.7 (23.0-29.6) 26.0 (23.5-29.3) 27.1 (24.4-30.7) 26.0 (23.7-30.3) 27.2 (24.3-30.9) 26.0 (23.4-29.5) 
Oral contraceptive (ever) use (%)† 89.2 92.2 79.3 80.3 78.9 78.9 82.0 
Hormone replacement therapy (%)π        
     Never used 96.7 95.5 55.3 39.7 51.6 14.8 61.3 
     Ex-user 1.9 3.2 39.6 49.2 40.4 64.6 32.9 
     Current user 1.4 1.3 5.1 11.1 8.0 20.6 5.8 
Live births (%)÷        
     0 25.4 25.3 16.2 10.4 22.0 15.4 17.9 
     1-2 55.1 55.9 58.8 59.3 49.5 58.0 58.0 
     3-4 18.4 17.7 23.5 28.2 26.2 24.9 22.7 
     5+ 1.1 1.1 1.5 2.1 2.3 1.7 1.4 
Smoking status (%)****        
     Lifetime non-smoker 64.5 64.7 58.2 57.8 55.4 57.3 59.7 
     Ex-smoker 25.4 25.6 33.9 33.0 34.6 33.3 31.6 
     Current smoker 10.1 9.7 7.9 9.2 10.0 9.4 8.7 
Pack-years, median (IQR)¥ 12.8 (6.8-21.0) 13.0 (6.5-22.0) 18.0 (9.0-30.0) 19.0 (10-0-30.8) 22.0 (10.5-30.0) 19.5 (10.0-31.7) 16.5 (8.5-28.0) 
Townsend deprivation index, median (IQR)€ -1.9 (-3.5, 0.8) -2.2 (-3.6, 0.4) -2.3 (-3.7, 0.0) -2.3 (-3.7, 0.2) -2.1 (-3.7, 0.7) -2.3 (-3.7, 0.3) -2.2 (-3.7, 0.2) 
FVC (L), median (IQR) 3.51 (3.14-3.91) 3.45 (3.09-3.84) 3.02 (2.66-3.40) 3.01 (2.64-3.40) 3.02 (2.60-3.44) 2.98 (2.62-3.37) 3.13 (2.74-3.55) 
FVC %predicted, median (IQR) 96.1 (87.6-104.7) 95.6 (86.6-104.2) 93.5 (84.2-102.7) 92.7 (83.5-102.0) 91.8 (81.1-101.6) 92.5 (83.0-101.7) 94.0 (84.8-103.1) 
FEV1 (L/s), median (IQR) 2.75 (2.44-3.05) 2.70 (2.40-3.00) 2.30 (2.00-2.61) 2.30 (2.00-2.61) 2.32 (1.97-2.67) 2.28 (1.98-2.59) 2.40 (2.08-2.74) 
FEV1 %predicted, median (IQR) 93.9 (84.9-102.6) 93.6 (84.5-102.4) 92.2 (81.9-101.9) 91.7 (81.6-101.5) 92.1 (79.5-101.8) 91.4 (81.2-101.3) 92.5 (82.5-102.0) 
FVC < LLN (%) 12.3 13.3 15.5 16.9 22.4 17.6 15.0 
FEV1/FVC < LLN (%) 8.9 8.0 8.7 7.4 4.7 7.9 8.6 
Doctor-diagnosed asthma (%) 13.1 13.6 11.4 14.5 13.6 13.9 12.3 
Wheeze in last year (%) 16.6 16.7 17.1 22.2 24.6 21.6 17.8 
Doctor-diagnosed COPD (%) 0.03 0.02 0.31 0.49 0.47 0.30 0.26 
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IQR, interquartile range. ‡3,898 missing (regular: 832; irregular: 230; natural: 2,276; hysterectomy only: 277; oophorectomy only: 9; oophorectomy + hysterectomy: 274). 
*5,258 missing (natural: 4,686; hysterectomy only: 297; oophorectomy only: 27; oophorectomy + hysterectomy: 248). **81 missing (regular: 12; irregular: 1; natural: 47; 
hysterectomy only: 8; oophorectomy + hysterectomy: 13). ***1,765 missing (regular: 273; irregular: 75; natural: 1,065: hysterectomy only: 189; oophorectomy only: 6; 
oophorectomy + hysterectomy: 157). †289 missing (regular: 62; irregular: 9; natural: 154; hysterectomy only: 30; oophorectomy only: 1; oophorectomy + hysterectomy: 
33). Π303 missing (regular: 77; irregular: 16; natural: 159; hysterectomy only: 27; oophorectomy only: 1; oophorectomy + hysterectomy: 23). ÷74 missing (regular: 13; 
irregular: 1; natural: 44; hysterectomy only: 10; oophorectomy + hysterectomy: 6). ****2,611 missing (regular: 435; irregular: 101; natural: 1,605; hysterectomy only: 263; 
oophorectomy only: 3; oophorectomy + hysterectomy: 204). ¥17,129 missing (natural: 3,576; irregular: 707; natural: 10,153; hysterectomy only: 1,514; oophorectomy only: 
29; oophorectomy + hysterectomy: 1,150). €163 missing (regular: 49; irregular: 9; natural: 80; hysterectomy only: 15; oophorectomy + hysterectomy: 10).  
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Table 2. Association of lung function with menstrual status.  
  FVC (mL) FEV1 (mL/s) FVC < LLN FEV1/FVC < LLN 
 N Difference (95% CI) Difference (95% CI) OR (95% CI) OR (95% CI) 
Main analysis (N = 115,848)      
Menstrual status      
   Regular menstruation 24,135 Ref. Ref. Ref. Ref. 
   Irregular menstruation 4,959 -17 (-31, -3) -12 (-24, 0) 1.16 (1.05-1.28) 0.95 (0.85-1.06) 
   Natural menopause 68,068 -42 (-53, -30) -34 (-43, -24) 1.27 (1.18-1.37) 1.03 (0.94-1.13) 
   Hysterectomy only 10,300 -51 (-64, -37) -32 (-43, -20) 1.31 (1.20-1.43) 0.86 (0.77-0.96) 
   Oophorectomy only 168 -90 (-159, -20) -46 (-105, 12) 1.69 (1.14-2.50) 0.64 (0.33-1.23) 
   Oophorectomy + hysterectomy 8,218 -54 (-69, -39) -33 (-46, -21) 1.36 (1.24-1.50) 0.87 (0.77-0.98) 
      
Sensitivity analysis* (N = 33,406)      
Menstrual status      
   Regular menstruation 11,131 Ref. Ref. Ref. Ref. 
   Irregular menstruation 2,261 -29 (-50, -8) -21 (-38, -4) 1.19 (1.00-1.40) 0.93 (0.77-1.14) 
   Natural menopause 17,910 -38 (-58, -19) -27 (-43, -10) 1.32 (1.13-1.54) 0.97 (0.80-1.18) 
   Hysterectomy only 1,621 -61 (-88, -34) -42 (-64, -20) 1.28 (1.04-1.58) 0.97 (0.74-1.28) 
   Oophorectomy only 32 -118 (-277, 40) -52 (-182, 78) 1.23 (0.37-4.10) 0.53 (0.07-3.93) 
   Oophorectomy + hysterectomy 451 -60 (-106, -14) -34 (-71, 4) 1.28 (0.91-1.80) 1.05 (0.66-1.66) 
Model 3: Adjusted for centre, age, ethnicity, standing height, Townsend deprivation index, age at menarche, oral contraceptive use, hormone replacement therapy use, 
number of live births, smoking status, pack-years, and body mass index. *Among White women, who have never smoked, have a body mass index of 18.5-29.99 kg/m2, do 
not have doctor-diagnosed asthma or chronic obstructive pulmonary disease (COPD), and have never used hormone replacement therapy. 
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Figures’ legends 
Figure 1. Selection of participants in the study. *At least one of female genital tract cancer; ovarian cancer; 
uterine/endometrial cancer; cervical cancer; vaginal cancer; vulval cancer; CIN/pre-cancer cells cervix; 
fallopian tube cancer. 
 
Figure 2. Association of FVC (mL) with age at natural menopause, by age group. Reference group is 
women who had menopause at 48-53 years. 
 
Figure 3. Association of spirometric restriction (FVC<LLN) with age at natural menopause, by age group. 
Reference group is women who had menopause at 48-53 years. 
 
Figure 4. Association of airflow obstruction (FEV1/FVC<LLN) with age at natural menopause, by age 
group. Reference group is women who had menopause at 48-53 years. 
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Supplementary table 1 shows that ever users of hormonal replacement therapy (HRT) were more likely to be ever 
smokers and heavier than those who have never taken HRT. 
 
Supplementary table 2 summarizes the characteristics of women from UK Biobank excluded from this study due to 
low quality of spirometry, and shows that these women were similar to those included in this 
analyses. 
 
Supplementary table 3 shows how the differences in lung function between women who had undergone either 
natural or surgical cessation of menstruation and women still menstruating are explained by 
demographic (model 1), plus reproductive (model 2), and lifestyle-related characteristics 
(model 3). 
 
Supplementary table 4 shows that our main findings are unlikely to be confounded by ethnicity, smoking status, 
body mass index (BMI), asthma, COPD, or use of HRT. The exception to this is the association 
of airflow obstruction (FEV1/FVC<LLN) with hysterectomy with or without oophorectomy 
which seems to be explained by smoking, BMI, and use of HRT. 
 
Supplementary table 5 shows that among postmenopausal women, the earlier they underwent natural menopause, 
the lower their FVC. This finding is unlikely to be affected by HRT, smoking or BMI. 
 
Supplementary table 6 shows that among postmenopausal women, the earlier they underwent natural menopause, 
the lower their FEV1. This finding is unlikely to be affected by HRT, smoking or BMI. 
 
Supplementary table 7 shows that among postmenopausal women, the earlier they underwent natural menopause, 
the higher their risk of spirometric restriction (FVC<LLN). This finding is unlikely to be 
affected by HRT, smoking or BMI. 
 
Supplementary table 8 shows that among postmenopausal women there was no clear association of airflow 
obstruction with age at natural menopause. This finding is unlikely to be affected by HRT, 
smoking or BMI. 
 
Supplementary table 9 shows that among women who had hysterectomy, and never used HRT, there was no clear 
association of lung function (FVC, FEV1, FVC<LLN, FEV1/FVC<LLN) with age at hysterectomy.  
 
Supplementary table 10 shows that among women who had oophorectomy+hysterectomy, and never used HRT, 
there was no clear association of lung function (FVC, FEV1, FVC<LLN, FEV1/FVC<LLN) with 
age at oophorectomy+hysterectomy.
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Supplementary table 1. Distribution of body mass index and smoking status according to hormonal replacement therapy status. 
 HRT 
 
Never users Ever users 
 
BMI (kg/m2), median (IQR)* 25.8 (23.2-29.4) 26.3 (23.8-29.6) 
BMI (kg/m2), (%)*   
     <18.5 0.6 0.4 
     18.5-24.99 41.4 35.9 
     25.00-29.99 35.8 40.4 
     30+ 22.2 23.3 
Smoking status (%)**   
     Lifetime non-smoker 63.3 53.9 
     Ex-smoker 28.1 37.3 
     Current smoker 8.6 8.8 
IQR, interquartile range. *1,765 missing. **2,611 missing. 
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Supplementary table 2. Characteristics of women in UK Biobank excluded from this study (with at least two spirograms without cough and back-extrapolated volume <5% 
FVC (or <150mL if greater), but excluding those with FET ≥6s on best curve (highest FEV1 + FVC)). Women who: 1) used inhaler in the last hour; 2) were unsure whether 
they had menopause; 3) were pregnant; 4) had gynaecologic cancer; and 5) reported an age at menopause <35 or >65 are not included. 
 
Regular 
menstruation 
Irregular 
menstruation 
Natural 
menopause 
Surgical interventions before menopause 
Total population 
 
Hysterectomy 
only 
Oophorectomy 
only 
Oophorectomy + 
hysterectomy 
N 18,381 3,728 47,152 7,126 142 5,710 82,239 
Age (years), median (IQR) 45 (43-48) 47 (44-50) 61 (56-64) 60 (55-65) 57 (50-62) 61 (55-65) 57 (49-63) 
Age at menarche (years), median (IQR)‡ 13 (12-14) 13 (12-14) 13 (12-14) 13 (12-14) 13 (12-14) 13 (12-14) 13 (12-14) 
Age at cessation of menstruation (years), 
median (IQR)* 
- - 50 (48-53) 41 (37-45) 42 (37-50) 45 (40-50) - 
Ethnicity (%)        
     White 89.5 93.1 94.6 93.7 86.6 93.2 93.2 
     Non-White 10.5 6.9 5.4 6.3 13.4 6.8 6.8 
Standing height (cm), median (IQR)** 164 (160-169) 164 (160-169) 162 (158-166) 162 (158-166) 161 (158-166) 162 (158-166) 163 (158-167) 
BMI (kg/m2), median (IQR)*** 25.0 (22.4-28.6) 25.3 (22.7-29.2) 26.1 (23.5-29.6) 27.2 (24.4-30.8) 27.2 (24.0-31.1) 27.4 (24.5-31.1) 26.0 (23.3-29.6) 
Oral contraceptive (ever) use (%)† 87.1 89.7 76.9 77.9 73.9 76.2 79.8 
Hormone replacement therapy (%)π        
     Never used 96.9 96.0 57.4 42.4 53.9 16.7 63.9 
     Ex-user 1.9 2.7 37.9 47.6 37.6 63.9 30.9 
     Current user 1.2 1.3 4.7 10.0 8.5 19.4 5.2 
Live births (%)÷        
     0 27.0 25.5 17.8 11.7 19.7 16.5 19.6 
     1-2 54.0 55.7 57.6 57.6 57.8 57.2 56.7 
     3-4 17.7 18.0 22.8 28.4 21.1 24.1 22.0 
     5+ 1.3 0.8 1.7 2.4 1.4 2.2 1.7 
Smoking status (%)****        
     Lifetime non-smoker 69.1 69.7 63.3 63.7 69.3 63.8 64.9 
     Ex-smoker 21.3 21.3 29.1 28.2 17.1 27.8 26.8 
     Current smoker 9.6 9.0 7.6 8.1 13.6 8.4 8.3 
Pack-years, median (IQR)¥ 12.2 (6.8-20.2) 13.0 (7.0-21.9) 18.0 (9.0-30.0) 19.5 (9.8-30.8) 22.0 (10.8-33.9) 19.5 (10.0-31.3) 16.5 (8.5-28.0) 
Townsend deprivation index, median (IQR) € -1.8 (-3.5, 1.0) -2.05 (-3.6, 0.6) -2.2 (-3.7, 0.3) -2.2 (-3.7, 0.3) -1.0 (-3.3, 1.9) -2.1 (-3.6, 0.6) -2.1 (-3.6, 0.5) 
FVC (L), median (IQR) 3.54 (3.11-3.99) 3.49 (3.09-3.92) 3.05 (2.65-3.48) 3.04 (2.62-3.48) 3.06 (2.57-3.55) 3.00 (2.58-3.43) 3.17 (2.73-3.63) 
FVC %predicted, median (IQR) 96.1 (86.1-105.7) 95.7 (86.3-105.2) 94.0 (83.5-104.6) 93.3 (82.3-104.0) 91.0 (80.2-102.7) 92.3 (81.7-102.9) 94.4 (84.0-104.7) 
FEV1 (L/s), median (IQR) 2.78 (2.43-3.11) 2.74 (2.42-3.08) 2.32 (2.00-2.65) 2.33 (1.99-2.66) 2.33 (1.81-2.73) 2.30 (1.96-2.62) 2.43 (2.08-2.80) 
FEV1 %predicted, median (IQR) 94.1 (84.2-103.6) 94.7 (84.7-104.2) 92.8 (81.7-103.2) 92.4 (80.9-102.7) 89.2 (73.1-100.8) 91.4 (80.6-102.0) 93.0 (82.3-103.2) 
FVC < LLN (%) 15.8 15.4 17.8 20.0 22.5 21.2 17.7 
FEV1/FVC < LLN (%) 13.1 10.8 13.1 12.2 16.2 12.0 12.8 
Doctor-diagnosed asthma (%) 10.6 11.0 8.8 12.1 12.9 12.0 9.8 
Wheeze in last year (%) 14.9 15.4 15.2 20.0 30.7 20.0 15.9 
Doctor-diagnosed COPD (%) 0.04 0.05 0.19 0.25 0.70 0.30 0.16 
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IQR, interquartile range. ‡2,613 missing (regular: 595; irregular: 140; natural: 1,484; hysterectomy only: 174; oophorectomy only: 2; oophorectomy + hysterectomy: 218). 
*3,324 missing (natural: 2,897; hysterectomy only: 214; oophorectomy only: 26; oophorectomy + hysterectomy: 187). **93 missing (regular: 16; irregular: 5; natural: 55; 
hysterectomy only: 8; oophorectomy + hysterectomy: 9). ***1,214 missing (regular: 231; irregular: 49; natural: 741: hysterectomy only: 100; oophorectomy only: 4; 
oophorectomy + hysterectomy: 89). †259 missing (regular: 71; irregular: 15; natural: 134; hysterectomy only: 12; oophorectomy + hysterectomy: 27). Π327 missing (regular: 
86; irregular: 17; natural: 168; hysterectomy only: 32; oophorectomy only: 1; oophorectomy + hysterectomy: 23). ÷88 missing (regular: 22; irregular: 1; natural: 55; 
hysterectomy only: 5; oophorectomy + hysterectomy: 5). ****1,552 missing (regular: 277; irregular: 51; natural: 972; hysterectomy only: 150; oophorectomy only: 2; 
oophorectomy + hysterectomy: 100). ¥10,857 missing (natural: 2,357; irregular: 433; natural: 6,382; hysterectomy only: 898; oophorectomy only: 17; oophorectomy + 
hysterectomy: 770). €95 missing (regular: 24; irregular: 5; natural: 57; hysterectomy only: 3; oophorectomy + hysterectomy: 6). 
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Supplementary table 3. Association of lung function with menstrual status.  
 
Unadjusted 
(N = 141,076) 
Model 1 
(N = 140,833) 
Model 2 
(N = 136,388) 
Model 3 
(N = 115,848) 
 Difference (95% CI) Difference (95% CI) Difference (95% CI) Difference (95% CI) 
FVC (mL)     
  Regular menstruation Ref. Ref. Ref. Ref. 
  Irregular menstruation -53 (-69, -37) -29 (-42, -16) -28 (-41, -15) -17 (-31, -3) 
  Natural menopause -483 (-491, -475) -51 (-62, -41) -50 (-61, -39) -42 (-53, -30) 
  Hysterectomy only -493 (-505, -480) -75 (-88, -63) -76 (-89, -64) -51 (-64, -37) 
  Oophorectomy only -499 (-578, -421) -115 (-178, -51) -120 (-185, -55) -90 (-159, -20) 
  Oophorect. + hysterect. -519 (-532, -505) -86 (-99, -73) -86 (-100, -72) -54 (-69, -39) 
     
FEV1 (mL/s)     
  Regular menstruation Ref. Ref. Ref. Ref. 
  Irregular menstruation -45 (-58, -31) -18 (-30, -7) -19 (-30, -7) -12 (-24, 0) 
  Natural menopause -441 (-448, -435) -47 (-56, -38) -45 (-54, -36) -34 (-43, -24) 
  Hysterectomy only -434 (-444, -424) -53 (-64, -43) -51 (-62, -41) -32 (-43, -20) 
  Oophorectomy only -409 (-473, -345) -65 (-119, -12) -66 (-121, -12) -46 (-105, 12) 
  Oophorect. + hysterect. -456 (-467, -445) -63 (-74, -52) -57 (-69, -45) -33 (-46, -21) 
     
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
FVC < LLN     
  Regular menstruation Ref. Ref. Ref. Ref. 
  Irregular menstruation 1.10 (1.01-1.19) 1.20 (1.10-1.31) 1.19 (1.09-1.30) 1.16 (1.05-1.28) 
  Natural menopause 1.30 (1.25-1.36) 1.33 (1.25-1.42) 1.33 (1.24-1.42) 1.27 (1.18-1.37) 
  Hysterectomy only 1.44 (1.36-1.53) 1.46 (1.35-1.58) 1.47 (1.36-1.60) 1.31 (1.20-1.43) 
  Oophorectomy only 2.06 (1.49-2.84) 1.93 (1.37-2.71) 2.01 (1.42-2.84) 1.69 (1.14-2.50) 
  Oophorect. + hysterect. 1.52 (1.43-1.62) 1.54 (1.42-1.67) 1.57 (1.44-1.71) 1.36 (1.24-1.50) 
     
FEV1/FVC < LLN     
  Regular menstruation Ref. Ref. Ref. Ref. 
  Irregular menstruation 0.89 (0.80-0.98) 0.94 (0.84-1.04) 0.95 (0.85-1.05) 0.95 (0.85-1.06) 
  Natural menopause 0.97 (0.93-1.02) 1.15 (1.06-1.25) 1.14 (1.04-1.23) 1.03 (0.94-1.13) 
  Hysterectomy only 0.82 (0.76-0.89) 0.94 (0.85-1.03) 0.90 (0.82-1.00) 0.86 (0.77-0.96) 
  Oophorectomy only 0.50 (0.26-0.94) 0.56 (0.30-1.07) 0.58 (0.31-1.11) 0.64 (0.33-1.23) 
  Oophorect. + hysterect. 0.87 (0.80-0.95) 1.00 (0.90-1.11) 0.93 (0.84-1.04) 0.87 (0.77-0.98) 
Model 1: Adjusted for centre, age, ethnicity, standing height, and Townsend deprivation index. Model 2: Model 1 plus age at menarche, oral contraceptive use, hormone 
replacement therapy use, and number of live births. Model 3: Model 2 plus smoking status, pack-years, and body mass index. 
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Supplementary table 4. Association of lung function with menstrual status, after sensitivity analysis.  
 
White ethnicity 
(N = 110,475) 
Lifetime non-smoker 
(N = 78,739) 
18.5 to 29.99 kg/m2 
(N = 88,555) 
Without asthma/COPD 
(N = 101,519) 
Never used HRT 
(N = 71,397) 
White ethnicity + lifetime non-smoker + 18.5 
to 29.99 kg/m2 + without asthma/COPD + 
never used HRT 
(N = 33,406) 
 Difference (95% CI) Difference (95% CI) Difference (95% CI) Difference (95% CI) Difference (95% CI) Difference (95% CI) 
FVC (mL)       
   Regular menstruation Ref. Ref. Ref. Ref. Ref. Ref. 
   Irregular menstruation -22 (-36, -7) -20 (-37, -4) -15 (-31, 1) -18 (-33, -3) -19 (-34, -5) -29 (-50, -8) 
   Natural menopause -41 (-52, -29) -40 (-54, -27) -45 (-58, -32) -39 (-51, -27) -42 (-55, -29) -38 (-58, -19) 
   Hysterectomy only -49 (-63, -35) -49 (-65, -32) -55 (-71, -39) -49 (-63, -34) -58 (-75, -40) -61 (-88, -34) 
   Oophorectomy only -101 (-173, -28) -75 (-163, 12) -109 (-191, -26) -74 (-148, 0) -136 (-234, -38) -118 (-277, 40) 
   Oophorect. + hysterect. -52 (-67, -36) -50 (-68, -32) -57 (-74, -39) -54 (-70, -38) -59 (-87, -30) -60 (-106, -14) 
       
FEV1 (mL/s)       
   Regular menstruation Ref. Ref. Ref. Ref. Ref. Ref. 
   Irregular menstruation -16 (-29, -4) -13 (-27, 1) -11 (-25, 2) -12 (-24, 1) -14 (-26, -2) -21 (-38, -4) 
   Natural menopause -32 (-42, -22) -29 (-40, -17) -37 (-48, -26) -32 (-42, -22) -36 (-48, -25) -27 (-43, -10) 
   Hysterectomy only -31 (-42, -19) -27 (-41, -13) -36 (-49, -22) -31 (-43, -19) -44 (-58, -29) -42 (-64, -20) 
   Oophorectomy only -55 (-116, -19) -37 (-110, 36) -52 (-122, 17) -32 (-94, 29) -68 (-150, 15) -52 (-182, 78) 
   Oophorect. + hysterect. -31 (-44, -18) -28 (-43, -13) -36 (-51, -22) -35 (-48, -22) -38 (-62, -13) -34 (-71, 4) 
       
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
FVC < LLN (NHANES III)     
   Regular menstruation Ref. Ref. Ref. Ref. Ref. Ref. 
   Irregular menstruation 1.21 (1.09-1.33) 1.13 (1.01-1.27) 1.15 (1.03-1.30) 1.17 (1.05-1.30) 1.17 (1.06-1.29) 1.19 (1.00-1.40) 
   Natural menopause 1.27 (1.17-1.38) 1.24 (1.14-1.36) 1.33 (1.21-1.46) 1.27 (1.17-1.38) 1.27 (1.17-1.39) 1.32 (1.13-1.54) 
   Hysterectomy only 1.31 (1.19-1.44) 1.24 (1.11-1.38) 1.35 (1.21-1.50) 1.28 (1.16-1.41) 1.33 (1.20-1.49) 1.28 (1.04-1.58) 
   Oophorectomy only 1.84 (1.22-2.77) 1.23 (0.72-2.12) 1.96 (1.22-3.14) 1.61 (1.04-2.50) 1.74 (1.01-2.99) 1.23 (0.37-4.10) 
   Oophorect. + hysterect. 1.36 (1.23, 1.50) 1.29 (1.14-1.45) 1.41 (1.25-1.59) 1.39 (1.25-1.54) 1.34 (1.13-1.58) 1.28 (0.91-1.80) 
       
FEV1/FVC < LLN (NHANES III)     
   Regular menstruation Ref. Ref. Ref. Ref. Ref. Ref. 
   Irregular menstruation 0.96 (0.85-1.08) 0.94 (0.81-1.08) 0.96 (0.85-1.09) 0.93 (0.80-1.07) 0.95 (0.85-1.07) 0.93 (0.77-1.14) 
   Natural menopause 1.02 (0.93-1.13) 1.01 (0.90-1.14) 1.06 (0.96-1.17) 1.03 (0.92-1.15) 1.04 (0.93-1.15) 0.97 (0.80-1.18) 
   Hysterectomy only 0.87 (0.77-0.97) 0.87 (0.74-1.01) 0.89 (0.78-1.00) 0.83 (0.73-0.96) 1.01 (0.88-1.17) 0.97 (0.74-1.28) 
   Oophorectomy only 0.61 (0.30-1.21) 0.58 (0.21-1.59) 0.64 (0.30-1.33) 0.48 (0.19-1.19) 0.78 (0.33-1.83) 0.53 (0.07-3.93) 
   Oophorect. + hysterect. 0.86 (0.76-0.98) 0.87 (0.73-1.03) 0.94 (0.82-1.07) 0.86 (0.74-1.00) 0.92 (0.72-1.17) 1.05 (0.66-1.66) 
Model 3: Adjusted for centre, age, ethnicity, standing height, Townsend deprivation index, age at menarche, oral contraceptive use, hormone replacement therapy use, 
number of live births, smoking status, pack-years, and body mass index. 
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Supplementary table 5. Association of forced vital capacity (FVC) with age at natural menopause, by age group. 
  40-55 years  56-59 years  60-62 years  63-65 years  66-70 years 
 
N Difference 
(95% CI) 
N Difference 
(95% CI) 
N Difference 
(95% CI) 
N Difference 
(95% CI) 
N Difference 
(95% CI) 
FVC (mL)           
   Natural menopause at <45 years 1976 -48 (-74, -22) 1041 -52 (-82, -22) 1053 -36 (-65, -7) 1010 -23 (-53, 6) 1000 -41 (-71, -12) 
   Natural menopause at 45-47 years 2324 -25 (-48, -2) 1282 -23 (-51, 4) 1297 -5 (-32, 21) 1105 -1 (-29, 27) 1284 -12 (-39, 14) 
   Natural menopause at 48-53 years 9788 Ref. 8174 Ref. 7309 Ref. 5779 Ref. 5743 Ref. 
   Natural menopause at 54-55 years 703 10 (-27, 48) 2612 0 (-20, 20) 2351 -16 (-37, 4) 1831 7 (-16, 30) 1498 -10 (-35, 15) 
   Natural menopause at 56+ years - - 1147 -5 (-34, 23) 1710 -9 (-32, 15) 1393 21 (-5, 46) 1296 8 (-18, 35) 
 p-trend = 4.5x10-6 p-trend = 0.004 p-trend = 0.3 p-trend = 0.006 p-trend = 5.7x10-4 
FVC (mL) – excluding HRT ever users           
   Natural menopause at <45 years 992 -71 (-107, -35) 332 -70 (-121, -18) 361 -36 (-85, 12) 373 -27 (-74, 21) 508 -49 (-91, -7) 
   Natural menopause at 45-47 years 1656 -24 (-51, 3) 638 -36 (-74, 2) 558 -15 (-55, 25) 474 5 (-37, 48) 623 -2 (-41, 36) 
   Natural menopause at 48-53 years 7773 Ref. 5189 Ref. 3881 Ref. 2745 Ref. 2859 Ref. 
   Natural menopause at 54-55 years 573 35 (-8, 78) 1765 -2 (-27, 22) 1223 -30 (-58, -1) 845 22 (-12, 55) 696 30 (-7, 67) 
   Natural menopause at 56+ years - - 791 -5 (-39, 30) 877 -9 (-42, 24) 621 35 (-3, 73) 561 25 (-16, 65) 
 p-trend = 8.2x10-7 p-trend = 0.03 p-trend = 1.0 p-trend = 0.03 p-trend = 8.4x10-5 
FVC (mL) – excluding HRT ever users and 
ever smokers 
          
   Natural menopause at <45 years 613 -48 (-92, -3) 200 -79 (-144, -13) 224 2 (-59, 62) 214 -6 (-67, 56) 303 -11 (-64, 42) 
   Natural menopause at 45-47 years 1132 -22 (-55, 11) 422 -26 (-73, 20) 346 -17 (-67, 33) 311 24 (-27, 76) 412 -12 (-58, 35) 
   Natural menopause at 48-53 years 5537 Ref. 3710 Ref. 2770 Ref. 1891 Ref. 2059 Ref. 
   Natural menopause at 54-55 years 433 31 (-18, 80) 1326 -11 (-40, 18) 918 -36 (-70, -3) 613 32 (-7, 71) 512 17 (-25, 60) 
   Natural menopause at 56+ years - - 590 -2 (-42, 38) 653 -18 (-56, 20) 465 42 (-2, 86) 434 29 (-17, 74) 
 p-trend = 0.004 p-trend = 0.2 p-trend = 0.2 p-trend = 0.2 p-trend = 0.02 
FVC (mL) – excluding HRT ever users, ever 
smokers, and extreme BMI 
          
   Natural menopause at <45 years 454 -47 (-98, 5) 149 -81 (-157, -5) 160 14 (-57, 85) 147 12 (-61, 85) 210 -14 (-78, 51) 
   Natural menopause at 45-47 years 885 -25 (-63, 12) 326 -37 (-89, 16) 275 -17 (-72, 39) 236 -9 (-68, 50) 324 -9 (-62, 45) 
   Natural menopause at 48-53 years 4380 Ref. 2953 Ref. 2153 Ref. 1482 Ref. 1608 Ref. 
   Natural menopause at 54-55 years 341 33 (-23, 88) 1055 -3 (-35, 29) 705 -29 (-67, 8) 474 40 (-4, 85) 386 6 (-44, 56) 
   Natural menopause at 56+ years - - 446 19 (-27, 65) 473 -10 (-54, 34) 325 23 (-29, 75) 326 22 (-32, 75) 
 p-trend = 0.007 p-trend = 0.07 p-trend = 0.4 p-trend = 0.4 p-trend = 0.1 
Model 3: Adjusted for centre, age, ethnicity, standing height, Townsend deprivation index, age at menarche, oral contraceptive use, hormone replacement therapy use, 
number of live births, smoking status, pack-years, and body mass index. Reference group: Women with natural menopause at age 48-53. P-trend is from model with age at 
menopause as continuous variable. 
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Supplementary table 6. Association of forced expiratory volume in 1 second (FEV1) with age at natural menopause, by age group. 
  40-55 years  56-59 years  60-62 years  63-65 years  66-70 years 
 
N Difference 
(95% CI) 
N Difference 
(95% CI) 
N Difference 
(95% CI) 
N Difference 
(95% CI) 
N Difference 
(95% CI) 
FEV1 (mL/s)           
   Natural menopause at <45 years 1976 -41 (-63, -19) 1041 -44 (-69, -19) 1053 -36 (-60, -11) 1010 -24 (-49, 1) 1000 -30 (-55, -5) 
   Natural menopause at 45-47 years 2324 -26 (-45, -7) 1282 -11 (-34, 12) 1297 -3 (-25, 19) 1105 -13 (-37, 11) 1284 -15 (-38, 8) 
   Natural menopause at 48-53 years 9788 Ref. 8174 Ref. 7309 Ref. 5779 Ref. 5743 Ref. 
   Natural menopause at 54-55 years 703 -2 (-33, 30) 2612 6 (-11, 23) 2351 -13 (-31, 4) 1831 2 (-18, 21) 1498 -2 (-23, 20) 
   Natural menopause at 56+ years - - 1147 -4 (-29, 20) 1710 -3 (-23, 17) 1393 19 (-3, 40) 1296 6 (-17, 28) 
 p-trend = 1.1x10-5 p-trend = 0.002 p-trend = 0.05 p-trend = 6.2x10-4 p-trend = 6.9x10-4 
FEV1 (mL/s) – excluding HRT ever users           
   Natural menopause at <45 years 992 -54 (-84, -25) 332 -57 (-100, -14) 361 -38 (-78, 3) 373 -26 (-66, 14) 508 -49 (-85, -14) 
   Natural menopause at 45-47 years 1656 -24 (-47, -2) 638 -19 (-51, 12) 558 -17 (-51, 16) 474 -13 (-49, 23) 623 -10 (-43, 22) 
   Natural menopause at 48-53 years 7773 Ref. 5189 Ref. 3881 Ref. 2745 Ref. 2859 Ref. 
   Natural menopause at 54-55 years 573 17 (-18, 53) 1765 3 (-17, 24) 1223 -20 (-44, 4) 845 8 (-20, 37) 696 25 (-6, 56) 
   Natural menopause at 56+ years - - 791 -2 (-31, 27) 877 -3 (-30, 25) 621 36 (3, 68) 561 21 (-13, 55) 
 p-trend = 6.6x10-6 p-trend = 0.01 p-trend = 0.3 p-trend = 0.005 p-trend = 1.5x10-5 
FEV1 (mL/s) – excluding HRT ever users and 
ever smokers 
          
   Natural menopause at <45 years 613 -38 (-75, -1) 200 -73 (-128, -18) 224 -2 (-52, 48) 214 -9 (-60, 42) 303 -10 (-54, 35) 
   Natural menopause at 45-47 years 1132 -18 (-45, 9) 422 -1 (-39, 38) 346 -21 (-62, 20) 311 15 (-28, 59) 412 -7 (-46, 32) 
   Natural menopause at 48-53 years 5537 Ref. 3710 Ref. 2770 Ref. 1891 Ref. 2059 Ref. 
   Natural menopause at 54-55 years 433 11 (-30, 51) 1326 -7 (-32, 17) 918 -27 (-54, 1) 613 20 (-13, 53) 512 18 (-18, 54) 
   Natural menopause at 56+ years - - 590 -1 (-35, 32) 653 -12 (-43, 20) 465 39 (2, 76) 434 28 (-10, 67) 
 p-trend = 0.008 p-trend = 0.2 p-trend = 0.6 p-trend = 0.1 p-trend = 0.02 
FEV1 (mL/s) – excluding HRT ever users, ever 
smokers, and extreme BMI 
          
   Natural menopause at <45 years 454 -37 (-80, 6) 149 -72 (-134, -9) 160 8 (-51, 68) 147 0 (-61, 61) 210 -6 (-60, 48) 
   Natural menopause at 45-47 years 885 -20 (-51, 11) 326 -13 (-57, 30) 275 -19 (-65, 27) 236 -8 (-57, 41) 324 -4 (-49, 40) 
   Natural menopause at 48-53 years 4380 Ref. 2953 Ref. 2153 Ref. 1482 Ref. 1608 Ref. 
   Natural menopause at 54-55 years 341 11 (-35, 57) 1055 -1 (-28, 26) 705 -21 (-52, 11) 474 30 (-7, 67) 386 7 (-35, 48) 
   Natural menopause at 56+ years - - 446 10 (-28, 48) 473 -4 (-41, 33) 325 18 (-25, 62) 326 23 (-21, 68) 
 p-trend = 0.02 p-trend = 0.1 p-trend = 0.8 p-trend = 0.3 p-trend = 0.1 
Model 3: Adjusted for centre, age, ethnicity, standing height, Townsend deprivation index, age at menarche, oral contraceptive use, hormone replacement therapy use, 
number of live births, smoking status, pack-years, and body mass index. Reference group: Women with natural menopause at age 48-53. P-trend is from model with age at 
menopause as continuous variable. 
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Supplementary table 7. Association of spirometric restriction (FVC<LLN) with age at natural menopause, by age group. 
  40-55 years  56-59 years  60-62 years  63-65 years  66-70 years 
 N OR (95% CI) N OR (95% CI) N OR (95% CI) N OR (95% CI) N OR (95% CI) 
FVC < LLN           
   Natural menopause at <45 years 1976 1.05 (0.90-1.23) 1041 1.40 (1.18-1.66) 1053 1.21 (1.02-1.44) 1010 1.15 (0.95-1.38) 1000 1.19 (0.99-1.43) 
   Natural menopause at 45-47 years 2324 1.12 (0.98-1.28) 1282 1.06 (0.89-1.25) 1297 1.02 (0.86-1.20) 1105 1.06 (0.88-1.27) 1284 1.08 (0.91-1.28) 
   Natural menopause at 48-53 years 9788 Ref. 8174 Ref. 7309 Ref. 5779 Ref. 5743 Ref. 
   Natural menopause at 54-55 years 703 0.92 (0.73-1.17) 2612 0.92 (0.81-1.05) 2351 1.12 (0.98-1.27) 1831 0.99 (0.84-1.15) 1498 1.05 (0.90-1.24) 
   Natural menopause at 56+ years - - 1147 1.03 (0.86-1.24) 1710 1.13 (0.97-1.31) 1393 0.95 (0.80-1.13) 1296 0.95 (0.79-1.13) 
 p-trend = 0.1 p-trend = 5.4x10-4 p-trend = 0.8 p-trend = 0.05 p-trend = 0.02 
FVC < LLN – excluding HRT ever users           
   Natural menopause at <45 years 992 1.07 (0.87-1.32) 332 1.48 (1.11-1.98) 361 1.34 (1.00-1.80) 373 1.06 (0.79-1.44) 508 1.30 (1.02-1.67) 
   Natural menopause at 45-47 years 1656 1.09 (0.93-1.28) 638 1.03 (0.81-1.30) 558 1.34 (1.04-1.71) 474 0.92 (0.69-1.23) 623 1.12 (0.88-1.42) 
   Natural menopause at 48-53 years 7773 Ref. 5189 Ref. 3881 Ref. 2745 Ref. 2859 Ref. 
   Natural menopause at 54-55 years 573 0.80 (0.61-1.05) 1765 0.94 (0.80-1.11) 1223 1.26 (1.05-1.52) 845 0.91 (0.72-1.14) 696 0.89 (0.70-1.13) 
   Natural menopause at 56+ years - - 791 1.03 (0.83-1.28) 877 1.09 (0.88-1.36) 621 0.84 (0.64-1.10) 561 0.78 (0.60-1.03) 
 p-trend = 0.05 p-trend = 0.08 p-trend = 0.5 p-trend = 0.3 p-trend = 5.8x10-4 
FVC < LLN – excluding HRT ever users 
and ever smokers 
          
   Natural menopause at <45 years 613 0.86 (0.65-1.13) 200 1.65 (1.14-2.38) 224 1.18 (0.80-1.74) 214 0.91 (0.58-1.41) 303 1.07 (0.75-1.52) 
   Natural menopause at 45-47 years 1132 1.03 (0.84-1.25) 422 0.98 (0.72-1.31) 346 1.07 (0.76-1.50) 311 0.81 (0.55-1.19) 412 1.17 (0.87-1.59) 
   Natural menopause at 48-53 years 5537 Ref. 3710 Ref. 2770 Ref. 1891 Ref. 2059 Ref. 
   Natural menopause at 54-55 years 433 0.80 (0.58-1.09) 1326 1.02 (0.85-1.23) 918 1.28 (1.02-1.59) 613 0.90 (0.68-1.20) 512 0.90 (0.67-1.21) 
   Natural menopause at 56+ years - - 590 1.03 (0.80-1.33) 653 1.07 (0.83-1.39) 465 0.74 (0.53-1.03) 434 0.71 (0.51-1.00) 
 p-trend = 0.7 p-trend = 0.4 p-trend = 0.5 p-trend = 0.6 p-trend = 0.01 
FVC < LLN – excluding HRT ever users, 
ever smokers, and extreme BMI 
          
   Natural menopause at <45 years 454 0.97 (0.70-1.35) 149 1.62 (1.03-2.53) 160 1.26 (0.77-2.04) 147 0.70 (0.38-1.29) 210 1.13 (0.73-1.76) 
   Natural menopause at 45-47 years 885 1.01 (0.80-1.29) 326 1.10 (0.78-1.55) 275 1.06 (0.70-1.59) 236 0.96 (0.61-1.52) 324 1.18 (0.83-1.68) 
   Natural menopause at 48-53 years 4380 Ref. 2953 Ref. 2153 Ref. 1482 Ref. 1608 Ref. 
   Natural menopause at 54-55 years 341 0.72 (0.50-1.06) 1055 0.94 (0.75-1.18) 705 1.34 (1.02-1.74) 474 0.84 (0.59-1.19) 386 1.01 (0.71-1.43) 
   Natural menopause at 56+ years - - 446 0.90 (0.66-1.24) 473 1.17 (0.86-1.61) 325 0.78 (0.51-1.18) 326 0.71 (0.48-1.07) 
 p-trend = 0.4 p-trend = 0.08 p-trend = 0.3 p-trend = 0.9 p-trend = 0.04 
Model 3: Adjusted for centre, age, ethnicity, standing height, Townsend deprivation index, age at menarche, oral contraceptive use, hormone replacement therapy use, 
number of live births, smoking status, pack-years, and body mass index. Reference group: Women with natural menopause at age 48-53. P-trend is from model with age at 
menopause as continuous variable. 
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Supplementary table 8. Association of airflow obstruction (FEV1/FVC<LLN) with age at natural menopause, by age group. 
  40-55 years  56-59 years  60-62 years  63-65 years  66-70 years 
 N OR (95% CI) N OR (95% CI) N OR (95% CI) N OR (95% CI) N OR (95% CI) 
FEV1/FVC < LLN           
   Natural menopause at <45 years 1976 1.21 (1.00-1.47) 1041 1.25 (1.01-1.55) 1053 1.19 (0.96-1.48) 1010 1.14 (0.91-1.44) 1000 1.00 (0.80-1.26) 
   Natural menopause at 45-47 years 2324 1.12 (0.95-1.33) 1282 0.89 (0.71-1.10) 1297 1.05 (0.86-1.30) 1105 1.23 (0.99-1.52) 1284 0.99 (0.81-1.22) 
   Natural menopause at 48-53 years 9788 Ref. 8184 Ref. 7309 Ref. 5779 Ref. 5743 Ref. 
   Natural menopause at 54-55 years 703 1.04 (0.76-1.43) 2612 0.85 (0.71-1.01) 2351 1.05 (0.88-1.25) 1831 1.08 (0.89-1.32) 1498 0.94 (0.76-1.15) 
   Natural menopause at 56+ years - - 1147 1.02 (0.80-1.29) 1710 0.88 (0.71-1.09) 1393 0.99 (0.79-1.24) 1296 1.01 (0.8q-1.26) 
 p-trend = 0.1 p-trend = 0.03 p-trend = 0.1 p-trend = 0.1 p-trend = 0.8 
FEV1/FVC < LLN – excluding HRT ever 
users 
          
   Natural menopause at <45 years 922 1.10 (0.84-1.44) 332 1.25 (0.86-1.81) 361 1.43 (1.00-2.05) 373 1.17 (0.79-1.71) 508 1.26 (0.92-1.71) 
   Natural menopause at 45-47 years 1656 1.16 (0.94-1.42) 638 0.85 (0.61-1.17) 558 1.09 (0.79-1.51) 474 1.39 (0.99-1.96) 623 1.12 (0.84-1.50) 
   Natural menopause at 48-53 years 7773 Ref. 5189 Ref. 3881 Ref. 2745 Ref. 2859 Ref. 
   Natural menopause at 54-55 years 573 1.00 (0.70-1.43) 1765 0.80 (0.64-1.01) 1223 1.09 (0.85-1.41) 845 1.13 (0.84-1.53) 696 0.93 (0.69-1.27) 
   Natural menopause at 56+ years - - 791 0.96 (0.71-1.31) 877 0.75 (0.54-1.05) 621 0.80 (0.54-1.18) 561 0.97 (0.69-1.35) 
 p-trend = 0.5 p-trend = 0.09 p-trend = 0.07 p-trend = 0.03 p-trend = 0.08 
FEV1/FVC < LLN – excluding HRT ever 
users and ever smokers 
          
   Natural menopause at <45 years 613 1.09 (0.74-1.61) 200 1.48 (0.88-2.49) 224 1.10 (0.61-1.99) 214 0.98 (0.50-1.92) 303 0.92 (0.55-1.51) 
   Natural menopause at 45-47 years 1132 1.14 (0.86-1.50) 422 0.59 (0.34-1.00) 346 1.28 (0.80-2.03) 311 1.12 (0.67-1.90) 412 1.03 (0.69-1.54) 
   Natural menopause at 48-53 years 5537 Ref. 3710 Ref. 2770 Ref. 1891 Ref. 2059 Ref. 
   Natural menopause at 54-55 years 433 1.05 (0.68-1.64) 1326 0.89 (0.68-1.18) 918 1.05 (0.75-1.47) 613 1.10 (0.74-1.64) 512 0.87 (0.59-1.29) 
   Natural menopause at 56+ years - - 590 1.06 (0.74-1.53) 653 0.82 (0.54-1.25) 465 0.87 (0.54-1.42) 434 0.90 (0.59-1.37) 
 p-trend = 0.8 p-trend = 0.4 p-trend = 0.4 p-trend = 0.8 p-trend = 0.6 
FEV1/FVC < LLN – excluding HRT ever 
users, ever smokers, and extreme BMI 
          
   Natural menopause at <45 years 454 1.12 (0.73-1.70) 149 1.50 (0.83-2.72) 160 0.88 (0.43-1.77) 147 1.29 (0.65-2.58) 210 0.79 (0.43-1.43) 
   Natural menopause at 45-47 years 885 1.04 (0.77-1.42) 326 0.65 (0.37-1.16) 275 1.30 (0.80-2.12) 236 1.24 (0.71-2.18) 324 0.99 (0.64-1.53) 
   Natural menopause at 48-53 years 4380 Ref. 2953 Ref. 2153 Ref. 1482 Ref. 1608 Ref. 
   Natural menopause at 54-55 years 341 1.08 (0.68-1.73) 1055 0.82 (0.60-1.13) 705 1.05 (0.73-1.51) 474 1.08 (0.69-1.67) 386 0.90 (0.59-1.37) 
   Natural menopause at 56+ years - - 446 1.17 (0.79-1.73) 473 0.86 (0.55-1.34) 325 0.94 (0.55-1.60) 326 0.80 (0.49-1.29) 
 p-trend = 0.8 p-trend = 0.6 p-trend = 0.7 p-trend = 0.5 p-trend = 0.6 
Model 3: Adjusted for centre, age, ethnicity, standing height, Townsend deprivation index, age at menarche, oral contraceptive use, hormone replacement therapy use, 
number of live births, smoking status, pack-years, and body mass index. Reference group: Women with natural menopause at age 48-53. P-trend is from model with age at 
menopause as continuous variable. 
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Supplementary table 9. Association of lung function with age at hysterectomy, by age group, among women who have never taken HRT. 
  40-55 years  56-59 years  60-62 years  63-65 years  66-70 years 
 
N Difference 
(95% CI) 
N Difference 
(95% CI) 
N Difference 
(95% CI) 
N Difference 
(95% CI) 
N Difference 
(95% CI) 
FVC (mL)           
   Hysterectomy at < 45 years 1424 8 (-25, 41) 421 -32 (-78, 14) 339 -44 (-94, 6) 303 -47 (-99, 5) 331 -19 (-70, 32) 
   Hysterectomy at 45-47 years 271 -46 (-104, 12) 119 -109 (-193, -25) 79 -26 (-126, 73) 82 -66 (-162, 30) 95 19 (-72, 111) 
   Natural menopause at 48-53 years 7773 Ref. 5189 Ref. 3881 Ref. 2745 Ref. 2859 Ref. 
   Hysterectomy at 48-53 years 173 -19 (-89, 52) 87 -8 (-106, 90) 90 -51 (-144, 43) 65 -11 (-118, 96) 75 12 (-90, 115) 
   Hysterectomy at 54-55 years 7 45 (-300, 391) 15 -9 (-243, 235) 9 83 (-210, 375) 5 91 (-290, 473) 6 99 (-258, 456) 
   Hysterectomy at 56+ years - - 7 -40 (-382, 303) 6 -276 (-634, 83) 11 -102 (-360, 156) 15 43 (-183, 269) 
 p-trend = 1.0 p-trend = 0.5 p-trend = 1.0 p-trend = 0.2 p-trend = 0.2 
FEV1 (mL/s)           
   Hysterectomy at < 45 years 1424 9 (-18, 37) 421 -33 (-71, 6) 339 -31 (-73, 10) 303 -39 (-83, 5) 331 -7 (-50, 36) 
   Hysterectomy at 45-47 years 271 -31 (-79, 18) 119 -81 (-151, -10) 79 2 (-82, 85) 82 -59 (-140, 23) 95 42 (-35, 119) 
   Natural menopause at 48-53 years 7773 Ref. 5189 Ref. 3881 Ref. 2745 Ref. 2859 Ref. 
   Hysterectomy at 48-53 years 173 -27 (-86, 33) 87 -10 (-92, 72) 90 -31 (-109, 48) 65 -8 (-99, 83) 75 40 (-47, 126) 
   Hysterectomy at 54-55 years 7 93 (-198, 383) 15 -7 (-202, 189) 9 64 (-181, 309) 5 80 (-245, 405) 6 85 (-216, 385) 
   Hysterectomy at 56+ years - - 7 -13 (-300, 274) 6 -153 (-453, 148) 11 -55 (-274, 165) 15 85 (-105, 276) 
 p-trend = 0.7 p-trend = 0.5 p-trend = 0.8 p-trend = 0.2 p-trend = 0.1 
      
 N OR (95% CI) N OR (95% CI) N OR (95% CI) N OR (95% CI) N OR (95% CI) 
FVC<LLN           
   Hysterectomy at < 45 years 1424 0.90 (0.74-1.10) 421 1.04 (0.78-1.37) 339 1.54 (1.15-2.07) 303 1.21 (0.87-1.67) 331 1.12 (0.82-1.52) 
   Hysterectomy at 45-47 years 271 1.20 (0.86-1.67) 119 1.01 (0.61-1.67) 79 0.72 (0.35-1.48) 82 1.38 (0.77-2.47) 95 0.80 (0.43-1.50) 
   Natural menopause at 48-53 years 7773 Ref. 5189 Ref. 3881 Ref. 2745 Ref. 2859 Ref. 
   Hysterectomy at 48-53 years 173 1.16 (0.76-1.75) 87 0.63 (0.33-1.23) 90 0.82 (0.42-1.60) 65 1.26 (0.62-2.53) 75 0.84 (0.42-1.65) 
   Hysterectomy at 54-55 years 7 0.95 (0.11-8.06) 15 0.94 (0.24-3.63) 9 0.96 (0.14-6.41) 5 1.00 (1.00-1.00) 6 1.40 (0.15-12.65) 
   Hysterectomy at 56+ years - - 7 0.91 (0.11-7.88) 6 3.18 (0.54-18.70) 11 2.28 (0.58-8.96) 15 1.00 (1.00-1.00) 
 p-trend = 0.3 p-trend = 0.7 p-trend = 0.07 p-trend = 0.2 p-trend = 0.9 
FEV1/FVC<LLN           
   Hysterectomy at < 45 years 1424 0.98 (0.76-1.28) 421 1.34 (0.94-1.90) 339 1.01 (0.65-1.57) 303 1.09 (0.67-1.77) 331 0.93 (0.61-1.43) 
   Hysterectomy at 45-47 years 271 0.88 (0.53-1.45) 119 0.97 (0.47-2.00) 79 1.64 (0.76-3.57) 82 0.83 (0.32-2.17) 95 0.38 (0.13-1.10) 
   Natural menopause at 48-53 years 7773 Ref. 5189 Ref. 3881 Ref. 2745 Ref. 2859 Ref. 
   Hysterectomy at 48-53 years 173 1.47 (0.88-2.44) 87 1.66 (0.81-3.38) 90 0.87 (0.36-2.12) 65 0.92 (0.31-2.66) 75 0.63 (0.24-1.67) 
   Hysterectomy at 54-55 years 7 1.00 (1.00-1.00) 15 1.00 (1.00-1.00) 9 3.11 (0.37-26.11) 5 1.00 (1.00-1.00) 6 2.08 (0.22-19.86) 
   Hysterectomy at 56+ years - - 7 1.00 (1.00-1.00) 6 1.00 (1.00-1.00) 11 1.00 (1.00-1.00) 15 0.71 (0.09-5.64) 
 p-trend = 0.1 p-trend = 0.6 p-trend = 0.7 p-trend = 0.2 p-trend = 0.2 
Model 3: Adjusted for centre, age, ethnicity, standing height, Townsend deprivation index, age at menarche, oral contraceptive use, HRT use, number of live births, smoking 
status, pack-years, and body mass index. Ref. group: Women with natural menopause at age 48-53. P-trend is from model with age at hysterectomy as continuous variable. 
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Supplementary table 10. Association of lung function with age at oophorectomy + hysterectomy, by age group, among women who have never taken HRT. 
  40-55 years  56-59 years  60-62 years  63-65 years  66-70 years 
 
N Difference/OR 
(95% CI) 
N Difference/OR 
(95% CI) 
N Difference/OR 
(95% CI) 
N Difference/OR 
(95% CI) 
N Difference/OR 
(95% CI) 
FVC (mL)           
Oophor.+hysterect. at < 45 years 82 -55 (-168, 58) 15 71 (-165, 307) 20 -54 (-250, 141) 36 -74 (-218, 70) 41 -179 (-317, -40) 
Oophor.+hysterect. at 45-47 years 65 70 (-46, 185) 13 -91 (-345, 162) 9 -167 (-459, 124) 8 -87 (-391, 217) 18 -57 (-264, 150) 
Natural menopause at 48-53 years 7773 Ref. 5189 Ref. 3881 Ref. 2745 Ref. 2859 Ref. 
Oophor.+hysterect. at 48-53 years 247 -55 (-116, 7) 121 20 (-64, 104) 94 87 (-5, 178) 80 -77 (-175, 21) 151 -2 (-75, 72) 
Oophor.+hysterect. at 54-55 years 2 -622 (-1267, 24) 7 -391 (-736, -47) 7 115 (-215, 445) 5 -54 (-439, 330) 7 272 (-59, 603) 
Oophor.+hysterect. at 56+ years - - 14 140 (-104, 383) 22 -1 (-188, 188) 15 -160 (-383, 63) 32 -69 (-225, 87) 
 p-trend = 0.5 p-trend = 0.5 p-trend = 0.9 p-trend = 1.0 p-trend = 0.2 
FEV1 (mL/s)           
Oophor.+hysterect. at < 45 years 82 -16 (-111, 79) 15 17 (-181, 215) 20 -28 (-191, 136) 36 -62 (-185, 60) 41 -114 (-231, 3) 
Oophor.+hysterect. at 45-47 years 65 91 (-6, 189) 13 -70 (-282, 142) 9 -101 (-345, 143) 8 -78 (-336, 179) 18 0 (-175, 174) 
Natural menopause at 48-53 years 7773 Ref. 5189 Ref. 3881 Ref. 2745 Ref. 2859 Ref. 
Oophor.+hysterect. at 48-53 years 247 -33 (-85, 19) 121 21 (-49, 92) 94 76 (-1, 152) 80 -60 (-143, 22) 151 24 (-38, 86) 
Oophor.+hysterect. at 54-55 years 2 -463 (-1007, 81) 7 -271 (-559, 17) 7 79 (-197, 355) 5 -100 (-426, 225) 7 229 (-51, 508) 
Oophor.+hysterect. at 56+ years - - 14 159 (-45, 363) 22 36 (-120, 192) 15 -109 (-298, 80) 32 -40 (-171, 92) 
 p-trend = 0.3 p-trend = 0.7 p-trend = 0.7 p-trend = 0.7 p-trend = 0.5 
      
 N OR (95% CI) N OR (95% CI) N OR (95% CI) N OR (95% CI) N OR (95% CI) 
FVC<LLN           
Oophor.+hysterect. at < 45 years 82 1.91 (1.05-3.49) 15 0.36 (0.05-2.84) 20 1.30 (0.40-4.15) 36 1.89 (0.87-4.09) 41 2.03 (0.98-4.21) 
Oophor.+hysterect. at 45-47 years 65 0.59 (0.26-1.33) 13 1.41 (0.30-6.70) 9 3.01 (0.64-14.25) 8 1.19 (0.19-7.29) 18 1.28 (0.39-4.15) 
Natural menopause at 48-53 years 7773 Ref. 5189 Ref. 3881 Ref. 2745 Ref. 2859 Ref. 
Oophor.+hysterect. at 48-53 years 247 1.22 (0.87-1.72) 121 0.81 (0.47-1.37) 94 0.51 (0.25-1.03) 80 1.29 (0.70-2.37) 151 0.85 (0.53-1.36) 
Oophor.+hysterect. at 54-55 years 2 9.57 (0.57-161.05) 7 8.24 (1.69-40.13) 7 1.17 (0.13-10.51) 5 2.70 (0.33-21.79) 7 0.53 (0.04-6.49) 
Oophor.+hysterect. at 56+ years - - 14 0.86 (0.18-4.04) 22 1.64 (0.54-5.02) 15 1.47 (0.41-5.20) 32 0.71 (0.24-2.08) 
 p-trend = 0.2 p-trend = 0.9 p-trend = 0.8 p-trend = 0.1 p-trend = 0.1 
FEV1/FVC<LLN           
Oophor.+hysterect. at < 45 years 82 1.92 (1.05-3.49) 15 0.36 (0.05-2.84) 20 1.30 (0.40-4.15) 36 1.89 (0.87-4.09) 41 2.03 (0.98-4.21) 
Oophor.+hysterect. at 45-47 years 65 0.59 (0.26-1.33) 13 1.41 (0.30-6.70) 9 3.01 (0.64-14.25) 8 1.19 (0.19-7.29) 18 1.28 (0.39-4.15) 
Natural menopause at 48-53 years 7773 Ref. 5189 Ref. 3881 Ref. 2745 Ref. 2859 Ref. 
Oophor.+hysterect. at 48-53 years 247 1.22 (0.87-1.72) 121 0.81 (0.47-1.37) 94 0.51 (0.25-1.03) 80 1.29 (0.70-2.37) 151 0.85 (0.53-1.36) 
Oophor.+hysterect. at 54-55 years 2 9.57 (0.57-161.05) 7 8.24 (1.69-40.13) 7 1.17 (0.13-10.51) 5 2.70 (0.33-21.79) 7 0.53 (0.04-6.49) 
Oophor.+hysterect. at 56+ years - - 14 0.86 (0.18-4.04) 22 1.64 (0.54-5.02) 15 1.47 (0.41-5.20) 32 0.71 (0.24-2.08) 
 p-trend = 0.2 p-trend = 0.8 p-trend = 0.8 p-trend = 0.1 p-trend = 0.1 
Model 3: Adjusted for centre, age, ethnicity, standing height, Townsend deprivation index, age at menarche, oral contraceptive use, HRT use, number of live births, smoking 
status, pack-years, and body mass index. Ref. group: Women with natural menopause at age 48-53. P-trend is from model with age at hysterectomy as continuous variable. 
Supplementary figure 1. Age at cessation of menstruation by menstrual status.
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